Journal of International Oncology ›› 2013, Vol. 40 ›› Issue (7): 526-529.doi: 10.3760/cma.j.issn.1673-422X.2013.07.016

Previous Articles     Next Articles

Advances in the the epidermal growth factor receptor tyrosine kinase inhibitors combined with chemotherapy for lung cancer treatment  

ZHANG  Bei-Bei, SONG  Zheng-Bo, ZHANG  Yi-Ping   

  1. Chemotherapy Center, Zhejiang Cancer Hospital, Hangzhou 310022, China
  • Online:2013-07-08 Published:2013-07-08
  • Contact: ZHANG Yi-Ping E-mail:zyp@medmail.com.cn

Abstract: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) show good efficacy for the lung cancer patients with EGFR mutations. Chemotherapy drugs are the first choices for the lung cancer patients with EGFR wild-type. In basic research, EGFR-TKIs combination with chemotherapy drugs show good synergy. But in clinical research, the timing of EGFR-TKIs combination with chemotherapy drugs is related to the efficacy.

Key words: Receptor, epidermal growth factor, Drug therapy, Lung neoplasms